

WHAT IS CLAIMED IS:

1. ~~A recombinant Sendai virus vector expressing chemokine.~~
2. The recombinant Sendai virus vector of claim 1, wherein said chemokine is CXC-chemokine or CC-chemokine.
3. The recombinant Sendai virus vector of claim 2, wherein said CXC-chemokine is stromal cell-derived factor α or stromal cell-derived factor β .
4. The recombinant Sendai virus vector of claim 3, wherein said vector is disseminative.
5. The recombinant Sendai virus vector of claim 3, wherein said vector is infectious and replicates autonomously, but is not disseminative.
6. ~~A method of producing chemokine which comprises inserting at least one chemokine gene into a Sendai virus vector, allowing the vector to produce chemokine, and recovering chemokine.~~
7. The method of claim 6, wherein said chemokine is CXC-chemokine or CC-chemokine.
8. The method of claim 6, wherein the step of recovering comprises the step of removing virions by centrifugation.
9. A method of treating human immunodeficiency virus infection, which comprises administering to human subjects a recombinant Sendai virus vector expressing CXC-chemokine or CC-chemokine and allowing the vector to express the chemokine in vivo.
10. A method of treating human immunodeficiency virus infection, which comprises collecting target cells from human subjects, infecting the cells with a recombinant Sendai virus vector expressing CXC-chemokine or CC-chemokine, and giving the infected cells back to the human subjects.
11. A pharmaceutical composition comprising a recombinant Sendai virus vector expressing stromal cell-derived factor α or stromal cell-derived factor β and a pharmaceutically acceptable carrier, wherein said vector is disseminative.
12. A pharmaceutical composition comprising a recombinant Sendai virus vector expressing stromal cell-derived factor α or stromal cell-derived factor β and a pharmaceutically acceptable carrier, wherein said vector is infectious and replicates autonomously, but is not disseminative.

13. A method of inhibiting HIV proliferation, which comprises infecting HIV-infected cells with a recombinant Sendai virus vector expressing chemokine and incubating the cells to allow production of chemokine.

add 13/7
add 13/7